An aseptic process simulation replicates the entire aseptic manufacturing and filling process using a suitable nutrient medium instead of the medicinal product. It verifies, under the most realistic and challenging conditions possible, whether personnel, equipment, environment, and workflow effectively control the risk of microbial contamination.
Simulation of the Actual Filling Process
The run includes not only the filling of containers but also the interventions and interruptions relevant to the process. These may include line setup, aseptic connections, component changes, planned breaks, and interventions due to malfunctions. The nutrient medium must then be incubated under conditions that can make microbial growth visible.
The simulation should cover the highest possible number of typical manual activities and also consider situations that create an increased risk of contamination. A very smooth test run without shift changes, format changes, and representative interventions would therefore not be a convincing model of routine operations. All assumptions regarding duration, number of units, and selection of interventions are justified in the protocol.
Evaluation of Growth and Deviations
The expected result is no growth in the incubated units. If growth is detected, an investigation begins, considering the organism, possible cause, affected process phase, and the significance of the run. A single positive finding must neither be automatically dismissed as irrelevant nor treated as definitive proof of a process failure without a root cause analysis.
For initial validation, Annex 1 requires at least three successful consecutive simulations covering all shifts. Ongoing re-qualification typically occurs twice a year for each aseptic filling line. Additional simulations may become necessary if equipment, operating procedures, shift models, or any other factor critical for sterility changes.
The choice of nutrient medium and its suitability testing are part of the simulation. The medium must be able to indicate a potential contamination event under the chosen incubation conditions; at the same time, its handling must not artificially simplify the process. In a process with long holding times, it is therefore also evaluated whether the simulated filling realistically reflects this temporal stress.
Interventions are distinguished into planned and unplanned activities. Planned activities, such as refilling stoppers, can be described in a standardized manner, while unplanned interventions occur, for example, after a malfunction. For both categories, the frequency, duration, and proximity to the open product to be simulated must be defined. Video recordings or detailed observation protocols can support the evaluation of individual interventions.
The program is related to environmental monitoring but is not the same. An unremarkable environmental trend does not replace a media fill run, because the latter tests the entire chain of human intervention, machine, and open product phase.
Distinction from Sterility Testing of the Finished Product
Aseptic process simulation is not a sterility test on a manufactured batch. It assesses the ability of the entire process to prevent contamination, whereas the sterility test examines a limited number of sampled finished product samples. A negative test of individual samples therefore cannot subsequently validate an aseptic process that was previously inadequately controlled.
The sterility test is a control measure at the end of a chain of Contamination Control Strategy, environmental monitoring, qualification, in-process controls, and batch documentation. Asepsis is created by the design and execution of the process, not by the laboratory result. Especially for small investigational medicinal product batches, the available sample quantity further limits the significance of a finished product test.
The batch size of the media fill run is based on the production that can be realistically simulated. The detailed Commission Guidelines C(2017) 8179 final state that the validation of aseptic processes for small batch sizes poses particular problems; in these cases, the number of filled units may correspond to the maximum number filled in production, and where practicable, more units should be filled with nutrient medium. For manual or semi-automatic filling and closing steps, they demand increased attention to staff training and the validation of individual personnel’s aseptic technique.
Significance for Clinical Trials
For sterile-filled study medication, manual or semi-automatic steps that actually occur with small batch sizes must also be simulated. An ampoule or vial line, for example, may require special interventions during rare format changes that do not occur in the routine of a large commercial run. The process simulation provides direct evidence of whether the planned clinical manufacturing process is aseptically controlled.
Full-service CROs like Mediconomics support the planning of manufacturing and packaging schedules around validated line windows, the coordination of documentation between sponsor and manufacturing site, and the tracking of aseptic deviations. Within the clinical supply chain, they can also ensure that release documents contain the necessary process evidence for sterile investigational medicinal products.
Frequently Asked Questions (FAQ)
Why is a nutrient medium used instead of the investigational medicinal product?
A suitable nutrient medium can indicate the entry of viable microorganisms through subsequent growth. This allows the critical aseptic execution to be tested without using the active substance or product formulation.
Must atypical interventions be considered in the media fill run?
Yes, if they can occur under realistic operating conditions and influence the contamination risk. Their selection and frequency must be justified based on risk.
What does a positive media fill run indicate?
It triggers a documented investigation. Its depth depends on the finding, the organism detected, the process conditions, and potential impacts on the aseptic state.
Regulatory References
- EudraLex Volume 4, Annex 1 “Manufacture of Sterile Medicinal Products” — regulates the planning, execution, and evaluation of aseptic process simulations.
- Detailed Commission Guidelines C(2017) 8179 final — address the validation of aseptic processes for small investigational medicinal product batches.
- Delegated Regulation (EU) 2017/1569 — regulates GMP principles for investigational medicinal products for human use.